You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

EU approval for Rinvoq to treat atopic dermatitis

The European Commission (EC) has approved Abbvie’s JAK inhibitor Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.